Doses studied
The Ipamorelin doses that appear in the literature — and the half-life that frames them.
What was administered, to which species, by which route, in published studies. None of this is a human dosing recommendation.
Read this first
This page reports the Ipamorelin doses that show up in published studies — nothing more. It is not a guide for taking the peptide, and it contains no instruction to use it. The most important number for dosing logic is the half-life: in humans, ipamorelin clears with a half-life of about 2 hours and produces a single growth-hormone pulse peaking near 40 minutes [2]. That short, predictable window is why study designs used frequent dosing. Below you will find the doses used in the human pharmacokinetic study, the one human clinical trial, and the main animal experiments, each with its species and route. Community 'stack' protocols that pair ipamorelin with CJC-1295 exist, but they have no peer-reviewed human dosing basis and are described here as anecdotal, not recommended.
Doses used in human studies
Two human datasets define the dosing record, and both used the intravenous route. The pharmacokinetic-pharmacodynamic study gave single intravenous infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes, one dose level per group of eight volunteers, and found dose-proportional kinetics across the whole range [2]. The Phase 2 postoperative-ileus trial used a fixed weight-based regimen: 0.03 mg/kg intravenously twice daily for up to seven days [3]. That trial missed its primary endpoint (25.3 h vs 32.6 h to first tolerated meal, p=0.15), so the 0.03 mg/kg twice-daily regimen is documented as studied-but-ineffective for that indication, not as a recommended dose [3]. There are no published human subcutaneous dosing data — the route most common in off-label use has never been characterized in a human trial.
Doses used in animal studies
The animal literature spans several routes. The rat bone-growth study used 18, 90, and 450 microg/day subcutaneously, divided three times daily for 15 days, and saw dose-dependent longitudinal bone growth [4]. The founding characterization established a swine growth-hormone ED50 of 2.3 nmol/kg intravenously [1]. The 2024 ferret cachexia study used 1-3 mg/kg intraperitoneally [5]. Across these, dosing was frequent or continuous — consistent with the short half-life and the single-pulse pharmacodynamics seen in humans [2]. In rats, plasma clearance was roughly five-fold lower than GHRP-6, and intranasal bioavailability was about 20% [7], while oral bioavailability is effectively nil for ipamorelin itself — only engineered analogs derived from its scaffold reached meaningful oral absorption (~10% in dogs) [11].
Routes studied and stability
Ipamorelin has been studied intravenously (human pharmacokinetics and clinical trials; rodent efficacy), subcutaneously (rodent bone and body-composition studies, and the dominant route in community use), intranasally (rodent pharmacokinetics, ~20% bioavailability [7]), and intraperitoneally (rodent and ferret efficacy) [5]. Oral administration applies only to engineered ipamorelin-derived analogs, not to ipamorelin itself, which is not orally bioavailable [11]. The route gap is worth stressing: the human pharmacokinetic constants — the ~2-hour half-life, the 0.078 L/h/kg clearance — were all measured by the intravenous route [2], while the route most common in off-label use, subcutaneous injection, has no published human pharmacokinetic characterization at all. As a peptide, ipamorelin is supplied as a lyophilized (freeze-dried) powder, either free base or acetate salt, and is reconstituted with bacteriostatic water for research handling. It is subject to degradation by heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction.
Why the half-life shapes the dosing logic
The dosing patterns in the literature are not arbitrary; they track the pharmacokinetics. Because ipamorelin clears with a terminal half-life of about 2 hours and produces a single discrete growth-hormone pulse that peaks near 40 minutes and then resolves, the molecule is essentially an event generator rather than a steady-state agent [2]. Each dose causes one pulse; sustained signaling would require repeated dosing. That is exactly what the animal studies did — three-times-daily subcutaneous dosing in the bone-growth work [4], twice-daily intravenous dosing in the human ileus trial [3], and frequent or continuous dosing across the rodent efficacy studies. The small steady-state volume of distribution (0.22 L/kg) reinforces the picture: the peptide stays mostly in the bloodstream, acts on its pituitary target, and is cleared, rather than accumulating in deep tissue [2]. Understanding that the dose is a trigger, not a reservoir, is the key to reading any ipamorelin dosing schedule in the literature.
How much cjc-1295 ipamorelin should i take
There is no established or studied human dose for the CJC-1295 + ipamorelin combination, and this site does not provide one. The combination has never been tested in a controlled human trial, so no dosing basis exists for it [3]. What the literature does provide is single-agent ipamorelin data — the human pharmacokinetic infusions of 4.21-140.45 nmol/kg IV [2] and the 0.03 mg/kg twice-daily intravenous regimen from the Phase 2 trial [3] — but those are study doses by the intravenous route, not personal recommendations, and the trial regimen did not meet its endpoint [3]. Community subcutaneous 'stack' protocols are anecdotal and have no peer-reviewed basis. No 'should-I-take' answer can be given without crossing into medical advice, which this editorial site does not do.
How to reconstitute cjc-1295 ipamorelin 5mg
Reconstitution of a lyophilized peptide such as ipamorelin (alone or in a combined vial) is a research-handling step, not a clinical procedure, and the specifics depend on the supplier's stated mass and the handler's intended working concentration. In general terms documented in the research-supply literature, lyophilized peptide is reconstituted with bacteriostatic water added slowly down the vial wall, then swirled rather than shaken to avoid shearing the peptide, and the resulting solution is kept refrigerated because peptides degrade with heat and repeated freeze-thaw. This site reports those handling observations as context only and gives no measured human-use preparation or dosing instruction [3].